Retaspimycin
Retaspimycin is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target heat shock protein HSP 90-alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
53 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | — | 1 | 2 | — | — | 2 |
| Plasma cell neoplasms | D054219 | — | — | — | 1 | 2 | — | — | 2 |
| Recurrence | D012008 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 1 | 2 | — | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Retaspimycin |
| INN | retaspimycin |
| Description | Retaspimycin is an ansamycin that is tanespimycin in which the benzoquinone moiety has been reduced to the corresponding hydroquinone. A semi-synthetic analogue of geldanamycin, it is used (generally as the hydrochloride salt) in cancer treatment. It has a role as a Hsp90 inhibitor and an antineoplastic agent. It is a member of hydroquinones, an ansamycin, an organic heterobicyclic compound, a secondary amino compound, a semisynthetic derivative and a carbamate ester. It is functionally related to a geldanamycin. It is a conjugate base of a retaspimycin(1+). |
| Classification | Small molecule |
| Drug class | antibiotics (Streptomyces strain) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C=CCNc1c(O)cc2c(O)c1C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)N2 |
Identifiers
| PDB | — |
| CAS-ID | 857402-23-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1184904 |
| ChEBI ID | 71975 |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | BZF2ZM0I5Z (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HSP90AA1
HSP90AA1
Organism
Homo sapiens
Gene name
HSP90AA1
Gene synonyms
HSP90A, HSPC1, HSPCA
NCBI Gene ID
Protein name
heat shock protein HSP 90-alpha
Protein synonyms
epididymis luminal secretory protein 52, epididymis secretory sperm binding protein Li 65p, Heat shock 86 kDa, heat shock 90kD protein 1, alpha, heat shock 90kD protein 1, alpha-like 4, heat shock 90kD protein, alpha-like 4, heat shock 90kDa protein 1, alpha, heat shock protein 90kDa alpha (cytosolic), class A member 1, heat shock protein 90kDa alpha family class A member 1, HSP 86, HSP86, LAP-2, Lipopolysaccharide-associated protein 2, LPS-associated protein 2, Renal carcinoma antigen NY-REN-38
Uniprot ID
Mouse ortholog
Hsp90aa1 (15519)
heat shock protein HSP 90-alpha (P07901)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 300 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use